These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32029495)

  • 1. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
    Craig Z; Swain J; Batman E; Wadsley J; Reed N; Faluyi O; Cave J; Sharma R; Chau I; Wall L; Lamarca A; Hubner R; Mansoor W; Sarker D; Meyer T; Cairns DA; Howard H; Valle JW; McNamara MG
    BMJ Open; 2020 Feb; 10(2):e034527. PubMed ID: 32029495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
    McNamara MG; Swain J; Craig Z; Sharma R; Faluyi O; Wadsley J; Morgan C; Wall LR; Chau I; Reed N; Sarker D; Margetts J; Krell D; Cave J; Sothi S; Anthoney A; Bell C; Patel A; Oughton JB; Cairns DA; Mansoor W; Lamarca A; Hubner RA; Valle JW
    EClinicalMedicine; 2023 Jun; 60():102015. PubMed ID: 37287870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
    Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
    JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
    Randrian V; Adenis A; Desrame J; Barbier E; Di Fiore F; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Breysacher G; Roquin G; Louafi S; Lopez A; Louvet C; Borg C; Metges JP; Faroux R; Gaba L; Manfredi S; Tougeron D
    Dig Liver Dis; 2020 Mar; 52(3):347-350. PubMed ID: 31899122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
    Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
    Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
    Gebauer F; Damanakis AI; Popp F; Quaas A; Kütting F; Lutz K; Held S; Deuß B; Göser T; Waldschmidt D; Bruns C
    BMC Cancer; 2021 Nov; 21(1):1239. PubMed ID: 34794396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
    Petrelli F; Parisi A; Tomasello G; Mini E; Arru M; Russo A; Garrone O; Khakoo S; Ardito R; Ghidini M
    BMC Gastroenterol; 2023 Jun; 23(1):212. PubMed ID: 37337148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
    van de Vlasakker VCJ; Guchelaar NAD; van den Heuvel TBM; Lurvink RJ; van Meerten E; Bax RJF; Creemers GM; van Hellemond IEG; Brandt-Kerkhof ARM; Madsen EVE; Nederend J; Koolen SLW; Nienhuijs SW; Kranenburg O; de Hingh IHJT; Verhoef C; Mathijssen RHJ; Burger JWA; ;
    BMJ Open; 2024 Jan; 14(1):e077667. PubMed ID: 38238055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
    Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
    Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
    Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
    Nagashima S; Kobayashi S; Tsunoda S; Yamachika Y; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
    Int J Clin Oncol; 2024 Feb; 29(2):188-194. PubMed ID: 37991558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.